Yun Jing Shuzhi (08147) issues a profit warning, expecting a mid-term loss of approximately HKD 4.4 million, a year-on-year increase.

20:31 27/08/2026

Yun Jing Smart Technology (08147) announced that, compared to a loss of approximately HKD 1.2 million for the same period in 2025, the Group expects to incur a loss of approximately HKD 4.4 million for the six months ending June 30, 2026, representing an expansion in the loss scale compared to the same period in 2025. The increase in loss is mainly due to higher sales and administrative expenses compared to the same period in 2025.

Yun Jing Smart Technology (08147) announced that, compared to a loss of approximately HKD 1.2 million for the same period in 2025, the Group anticipates a loss of approximately HKD 4.4 million for the six months ending June 30, 2026, indicating an expansion of the loss compared to the same period in 2025. The increase in the loss is primarily due to higher sales and administrative expenses compared to the same period in 2025.

IMMUNEONCO-B(01541): The first patient has been administered in the Phase II clinical trial of IMM2510 combined with IMM27M as first-line treatment for advanced HCC.

Suzhou Novosense Microelectronics (02676) announced its interim results, with a net profit attributable to the parent company of approximately 67.5918 million yuan, marking a turnaround from a loss to profit compared to the same period last year.

TYK MEDICINES-B(02410): The National Medical Products Administration has conditionally approved the marketing application for Dihydroartemisinin Mesylate Tablets (TY-9591 Tablets).

IMMUNEONCO-B(01541): The first patient has been administered in the Phase II clinical trial of IMM2510 combined with IMM27M as first-line treatment for advanced HCC.

TYK MEDICINES-B(02410): The National Medical Products Administration has conditionally approved the marketing application for Dihydroartemisinin Mesylate Tablets (TY-9591 Tablets).